Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
about
Current Trends of Renal Impairment in Multiple MyelomaLenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment.Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel anti-myeloma therapies.The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients.Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control StudyTherapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy.Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myelomaAnalysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaNew developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.Management of high-risk Myeloma: an evidence-based review of treatment strategies.Managing renal complications in multiple myeloma.Current treatments for renal failure due to multiple myeloma.Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.Recognition of early mortality in multiple myeloma by a prediction matrix.Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients.Sequential, Autologous Hematopoietic Stem Cell Transplant Followed by Renal Transplant in Multiple Myeloma.Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test.Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit.Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014.Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis.Renal recovery after severe acute kidney injury in critically ill myeloma patients: a retrospective study.Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
P2860
Q26740444-25D1E467-8A9B-408A-9D60-6FC4442A387CQ33418712-8E1D3398-DFAA-4728-964C-3E4631148AFDQ33426615-9C3DCC24-5CDD-4DB0-97C9-8654B487C476Q33434435-477261A7-94C4-485D-9BD7-08B73600E0D4Q33442039-632A5B31-68F9-4269-9BE0-7993B8B408E7Q33443274-45CB4E22-8668-48E8-81D3-F361A3D0BCB9Q33864162-B9F87CA4-DB74-4FD7-ADAC-73EC52C5F6DFQ35244883-A1442A5E-560B-483C-99E0-0F912C24DA3CQ35893993-D70B0BCF-B09D-4EFF-B315-DC3835BA3B0AQ36010511-B013BCB0-B639-4105-9C8A-8FBDB6963C31Q36088601-2771B3B0-F37D-4F2C-9F75-EF7A6731B244Q36750472-7F6309E9-7C4E-45C8-8EAF-47F9B0E5AC6CQ37216472-DA63E614-6180-455B-9A3D-C37ACD317F6AQ38598891-38CE97BE-98C1-4B46-A8B6-32194D769F1AQ38630472-5C4468FD-1832-4140-897B-443DA3B20C10Q38856521-AEC34E48-5C88-4B91-9518-346C068043BFQ38874675-E41DB579-3BF7-4757-82AC-2685C767A513Q38900024-6C9DA611-35A5-472F-A524-8D00EA0FB96DQ38959138-1DA0EEEE-E4FB-4F8A-98C5-FBD43F7CF1CFQ38976968-071BCC59-74A2-43F6-894A-F8D1B62B9E28Q38979403-61A020CB-23AB-4322-AFFF-4FF44329116FQ39273146-BEA00ACF-547E-4626-BE35-F877E07B2595Q39692801-143E4C6D-45AC-4748-A439-0BE548BB7139Q40185985-678E692D-AEA8-4ECE-9D68-A7312A2F3682Q40716636-A5737E03-29E8-4A38-B497-029174EF0E18Q41043529-57559D69-6E8F-4F4E-806A-A986E7ED496CQ41078986-2C101038-0F48-4081-8BD8-1489125F475AQ41080072-466ED3E2-DB94-4CB0-885A-3975691EB801Q42573839-9379FD8C-B98F-406D-99FC-C66127C9EE6BQ42921958-C27F3AB7-203E-488F-B8B9-33A7690A9F91Q44597478-023A4A46-56DA-4166-A554-D97CB76E6913Q47162496-E3BB0481-4934-495F-91B0-6DB3012CF537Q50089740-2572BE91-2F05-4635-B322-D7CDF5D5B786Q50100870-06789EE2-A908-4390-B802-AB315B2A01D0Q50105262-FD16D2A8-F01D-4A06-BD24-B587FD6186BEQ50934141-F45C2407-A2B1-4909-91D7-00A2154C7CC6
P2860
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Significant improvement in the ...... introduction of novel agents.
@en
Significant improvement in the ...... introduction of novel agents.
@nl
type
label
Significant improvement in the ...... introduction of novel agents.
@en
Significant improvement in the ...... introduction of novel agents.
@nl
prefLabel
Significant improvement in the ...... introduction of novel agents.
@en
Significant improvement in the ...... introduction of novel agents.
@nl
P2093
P2860
P50
P356
P1433
P1476
Significant improvement in the ...... e introduction of novel agents
@en
P2093
A Parcharidou
E Katodritou
E Michalis
K Konstantopoulos
M C Kyrtsonis
P Repousis
P2860
P304
P356
10.1093/ANNONC/MDT483
P577
2014-01-01T00:00:00Z